At an interview about the importance of the EFIC-GRÜNENTHAL Grant and special needs in pain research, with focus on major advances in the treatment of patients suffering from chronic pain. Dott. Alberto Grua, Member of the Corporate Executive Board, CCO EU, Australia and North-America, Grünenthal Group Dr. Matthias Müller, MD, MSc, SVP, Head of Medical Affairs, Grünenthal Europe & Australia and North America

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

Grünenthal Group

The Grünenthal Group

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.

Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 26 percent of revenues in 2012.


License Agreement

Grunenthal GmbH transfers license rights for Nucynta® (tapentadol) in the US from Janssen Pharmaceuticals, Inc., to Depomed, Inc.

Grünenthal GmbH granted its consent with Janssen Pharmaceuticals Inc.’s (JPI) divestment of the license rights for Nucynta® (tapentadol), Nucynta® ER (tapentadol) extended-release tablets and Nucynta® (tapentadol) oral solution in the U.S. territory to Depomed, Inc. (DEPO), the company announced today. During the transition period, the three companies work closely together for the ongoing support of these drugs.